Cost-Effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage
Stroke 37:2751-2758, Earnshaw,S.R.,et al, 2006
Diagnosis and Treatment of Ischemic Stroke
Am J Med 106:211-221, Alberts,M.J., 1999
Cost-Effectiveness of Intravenous Thrombolysis With Alteplase Within a 3-Hour Window After Acute Ischemic Stroke
Stroke 38:85-89, Ehlers,L.,et al, 2007
Estimated Cost Savings of Increased Use of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Canada
Storke 38:1952-1955,1732, Yip,T.R. &Demaerschalk,B.M., 2007
Long-Term Outcome After Thrombolysis in Telemedical Stroke Care
Neurol 69:898-903,819, Schwab,S.,et al, 2007
Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States
Stroke 36:2500-2503, Demaerschalk,B.M. &Yip,T.R., 2005
Surgical Decompression of Patients with Large Middle Cerebral Artery Infarcts is Effective
Stroke 34:2304-2305,2307, Schwab,S.&Hacke,W., 2003
Surgical Decopression of Patients With Large Middle Cerebral Artery Infarcts is Effective:Not Proven
Stroke 34:2305-2306,2307, Brown,M.M., 2003
Blood Pressure Control in Stroke Patients
Neurol 59:23-25, Messerli,F.H.,et al, 2002
Epidemiology of Recurrent Cerebral Infarction,A Medicare Claims-Based Comparison of First and Recurrent Strokes on 2-Year Survival and Cost
Stroke 30:338-349, Samsa,G.P.,et al, 1999
Predictors of Clinical Improvement,Angiographic Recanalization, and Intracranial Hemorrhage After Intra-Arterial Thrombolysis for Acute Ischemic Stroke
Stroke 30:2094-2100, Suarez,J.I.,et al, 1999
Early Intravenous Thrombolysis for Acute Ischemic Stroke in a Community-Based Approach
Stroke 29:1544-1549, Grond,M.,et al, 1998
Cost-Effectiveness of Tissue Plasminogen Activator for Acute Ischemic Stroke
Neurol 50:883-890, Fagan,S.C.,et al, 1998